Research and InnovationArticle
UTHealth Houston Opens Recruitment for the RESONATE Trial: Investigating a New Approach to Brain Stimulation for Depression
The Center for Interventional Psychiatry at UTHealth Houston has been activated for the RESONATE clinical trial, which investigates an emerging form of brain stimulation for adults living with treatment-resistant depression.
By João L. de Quevedo, MD, PhD
Published on · Last reviewed on · 4 min read
In this article
The Center for Interventional Psychiatry at UTHealth Houston is pleased to announce that our site has been activated for the RESONATE clinical trial and is now recruiting individuals who may qualify. The study investigates an emerging form of brain stimulation for adults living with treatment-resistant depression.
RESONATE—Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium—is sponsored by Motif Neurotech, a Houston-based neurotechnology company. It will study the safety, tolerability, and preliminary antidepressant effects of the investigational Motif eXternally powered Cortical Stimulation (XCS) System.
Why investigate another treatment for depression?
Major depressive disorder can be profoundly disabling, particularly when symptoms persist despite adequate trials of antidepressant treatment. Although medication, psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and other interventions help many patients, some continue to experience substantial symptoms and functional impairment.
Developing new approaches to neuromodulation is therefore an important research priority. RESONATE is one step in evaluating whether targeted cortical stimulation can eventually broaden the range of available treatment options.
What is the investigational Motif XCS System?
The system uses a small implanted device designed to deliver electrical stimulation near the left dorsolateral prefrontal cortex (DLPFC), a brain region involved in cognitive control and mood-related neural networks. The implant sits within an opening in the skull and contacts the dura, the protective covering of the brain, without penetrating it. An external wearable component supplies power and communicates with the implant.
This differs from TMS, which stimulates brain circuits noninvasively using magnetic fields, and from conventional deep brain stimulation, in which electrodes are placed deeper within the brain. The XCS approach is investigational; its benefits and risks for depression have not yet been established.
What will RESONATE study?
RESONATE is a multicenter, single-arm, open-label early feasibility study, meaning that all enrolled participants receive the investigational intervention and there is no randomized sham-control group. Its primary purpose is to characterize device- and procedure-related safety events over 12 months. Researchers will also examine changes in depressive symptoms and tolerability.
The study is designed to enroll a small number of participants nationally. Its findings will help determine whether and how larger, more definitive studies should be conducted. It should not be interpreted as evidence that this approach is already proven effective.
Who may qualify?
Potential participants are adults aged 22–85 with a current episode of nonpsychotic major depressive disorder and a history of inadequate sustained response to at least two appropriately dosed antidepressant treatments from different medication classes. Additional requirements and exclusions apply, including medical, psychiatric, imaging, and implanted-device considerations.
Participation involves screening and informed consent, evaluation for a surgical implant, a course of stimulation sessions, and follow-up assessments. Because this is an implanted investigational device, there are potential risks related to surgery, stimulation, infection, and other adverse events. The research team will review these risks and the alternatives in detail before anyone decides whether to participate.
An initial inquiry does not mean that a person is eligible or obligated to participate. Final eligibility is determined by the research team through the study screening process.
Our research team at UTHealth Houston
I serve as principal investigator for the activated UTHealth Houston site. Dr. Giselli Scaini oversees our research activities, working with our research coordinators and clinical collaborators. This effort brings together psychiatric research and neuromodulation expertise to evaluate a potentially important new technology with appropriate scientific and safety oversight.
We are currently accepting inquiries from prospective participants and referring clinicians. The study is registered as ClinicalTrials.gov NCT07594483.
Interested in learning more?
If you or someone you care for has depression that has not improved adequately with previous treatments, our team can discuss whether screening for RESONATE may be appropriate. The study is research, not established treatment, and participation is entirely voluntary.
For an inquiry about RESONATE, contact the Center for Interventional Psychiatry using the details below and specify “RESONATE trial” so your request can be directed to the research team.
Contact
Center for Interventional Psychiatry
UTHealth Houston Behavioral Health Sciences
Phone: (713) 486-2621
Email: CIP@uth.tmc.edu
Website: https://go.uth.edu/CIP
General second-opinion request: https://Go.uth.edu/CIPIntake
Please specify “RESONATE trial” when contacting the Center.
Disclaimer
The Motif XCS System is an investigational medical device being evaluated in a clinical study. Its safety and effectiveness for treatment-resistant depression have not been established. Study participation may involve surgery and other risks; eligibility, study procedures, potential benefits, alternatives, and risks are explained through the research informed-consent process. This article is educational and is not medical advice.
Artificial intelligence was used as a scientific writing support tool. The final text has been reviewed and approved by João L. de Quevedo, MD, PhD.
References
- ClinicalTrials.gov: RESONATE (NCT07594483) · clinicaltrials.gov
- Motif Neurotech · motifneuro.tech
- Original publication — UTHealth Houston Department of Psychiatry · med.uth.edu
Related content
Mood Disorders
The Intersection of Depression and ASD
Depression is a heavy burden for anyone, but for individuals on the autism spectrum, its weight can be particularly...
· Article
News
FDA Approves Zuranolone for Postpartum Depression
In a groundbreaking moment for mental health, the Food and Drug Administration (FDA) recently approved zuranolone, a new medication,...
· Research Radar
Research and Innovation
Group therapy with psilocybin may reduce depression in people with cancer
Psychedelic-assisted psychotherapy is typically offered in a private setting, involving one patient and two therapists. A...
· Research Radar